I got inspired by Raptor9's EV-4 on KerbalX, and so I decided to make my own long, orbitally assembled interplanetary ship. It assembled in three launches, but now that I'm ready to test it with a voyage to the Mun, the engine stats don't come up in the staging HUD. No ∆v, no TWR, no ISP, as if the engines were disabled (which they're not). I use Engineer so this wouldn't be a problem for me, except that this also has the effect of making the navball think I have 0 ∆v, and so when I make a maneuver node, the navball won't display burn time, which is incredibly inconvenient. I'm using three NERV engines mounted on an engine plate, if that helps. Here's what I've already ruled out:
All docking ports holding the vessel together have crossfeed enabled
Engines are enabled
Flow is not locked on any of the fuel tanks
Correct fuel is being used; the engines work and I can perform burns, the HUD just thinks I don't and can't
Staging display shows full liquid fuel bars for all three engines
Probe core is present and connected to KSC
Batteries are fully charged
This seems like an operator error issue, not a bug. What am I doing wrong?
Thinking of jumping into some LEAPS that expire either January 2022 or 2023, but not sure if that makes sense unless there will be a data readout by then? Do others have thoughts?
I went to Lilly’s website and went through all of their PR’s regarding bamlanivimab and here is what I found about the timeline of bamlanivimab trial:
My confusions are:
Followings are actual links of Lilly’s PR regarding bamlanivimab.
6/1/2020 --- First patient was dosed for P1 trial of LY-CoV555 (bamlanivimab)
- First patients have been dosed in a Phase 1 study of LY-CoV555, the lead antibody from Lilly's collaboration with AbCellera
- Should Phase 1 results show the antibody can be safely administered, Lilly will initiate a Phase 2 proof of concept study to assess efficacy in vulnerable populations
9/16/2020 --- Interim readout for P2 result
- Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting
- Primary endpoint of viral load change from baseline at day 11 was met for one of three doses: consistent effects of viral reduction seen at earlier time points
- Rate of hospitalizations and ER visits was 1.7 percent (5/302) for LY-CoV555 versus 6 percent (9/150) for placebo--a 72 percent risk reduction in... keep reading on reddit ➡
I have a max delta, from GPU temp, of about 16c during Timespy on my 3080 FE (repasted and repadded, so unsure if this is good)
https://www.hwinfo.com/download/ ("Primary Backup (U.S.)") https://imgur.com/a/tO5JBx0 https://www.hwinfo.com/files/hwi_643_4380.zip
EDIT: As an irrelevant but added bonus, for those who do not know, the latest Afterburner Beta 5 has hardware/firmware fan control, so you can have fan stop, and a custom fan curve, even with afterburner closed: MSI Afterburner 4.6.3 Beta 5 Download (guru3d.com)
Everyone on board constantly complained about this to Scotty, but he would tell them to just "feel the deck plates" if they wanted to know how fast they were going.
Figured I should do some quick summaries on some stock-moving data readouts due in Q1 that haven't come out yet. What good is being biotechplays if we don't have plays to look forward to?
$IMTX (Immatics NV) // Market Cap: ~767M
Immatics is a cell therapy-focused oncology company with a Phase 1 readout for three treatments at once. This is a company working on the novel technology of TCR-T -- the only other publicly traded company working on this is $ZIOP.
The three treatments work on separate types of cancer, with all having unique T-cell receptors and treating 10 patients or so in an open label safety/dosing trial. The patients all have various forms of cancers -- IMA201 is treating patients with small cell lung, head and neck, and bladder cancer. IMA202 is treating patients with liver cancer, lung cancer, and melanoma. IMA203 is treating patients with ovarian cancer, uterine cancer, melanoma, and lung cancer.
With four big pharma partnerships (GSK, BMY, AMGN, GMAB), I can imagine this being the more beloved Wall Street bet vs the poorly managed Ziopharm if there's no surprises in safety and even a few responses. This is an interim readout, so any sort of efficacious response here should be green.
On the other hand, if notable safety issues do pop up, the stock will be in some serious trouble.
For further DD -- Ian Henrich is one of the handful of people on SeekingAlpha that really knows what he's talking about and I'd recommend his writeup for it.
$LCTX (Lineage Cell Therapeutics) // Market Cap: ~386M
Lineage Cell Therapeutics is a cell therapy company with a Phase 1/2 readout for their dry AMD treatment OpRegen. This one is fun to read about for a few reasons. As a writeup on the space covers, dry AMD is the irreversible degeneration of the retina, leading to blindness. All of the approved and clinical drugs in the space work to slow the progression -- except for this drug which works to regenerate the retina.
They already released interim data for this study back in November however, and the stock dropped 10% on it. This is because they were unable to stop the spread of GA in the retina in many of the patients, even being unable to demonstrate stat sig differences in GA... keep reading on reddit ➡
Looks like the standard here. Saw prices in the $380's for a digital current readout but I saw some youtube videos where it was advised that practically it's much better to have the analog scale.
Specific unit I'm looking at. Below. Good buy? Par for course? Better deal elsewhere? Let me know!
In the span of about five minutes, remote hyperspace tracking goes from "impossible", to Rose saying it's "new tech", to Rose, Finn, and Poe looking at a schematic of the Supremacy's tracking device. Does anybody know how the Resistance got a complete technical readout of Snoke's ship and why they decided to leave it sitting around without analyzing it? Is there a novel or comic book that tries to damage control this?